Published • loading... • Updated
Eli Lilly (NYSE: LLY) Builds Multi-Product GLP-1 Platform As Revenue Surges 48% And Global Approvals Mount
Summary by foreignpolicyjournal.com
Read with caution - this story is only being covered by one news source that has a ‘low factuality’ rating, which means the outlet has a history of poor reporting practices. Learn more about factuality ratings here.1 Articles
1 Articles
Eli Lilly (NYSE: LLY) Builds Multi-Product GLP-1 Platform As Revenue Surges 48% And Global Approvals Mount
Eli Lilly (NYSE: LLY) reported 48% revenue growth in its second quarter, and the weeks since have brought a string of additional catalysts that extend well beyond a single blockbuster product. The UK’s Medicines and Healthcare products Regulatory Agency approved Foundayo, Lilly’s oral GLP-1, on August 10 for weight management and type 2 diabetes, making Britain the first European market to approve the pill. Lilly’s stock rose nearly 4% on the UK…
Coverage Details
Total News Sources1
Leaning Left1Leaning Right0Center0Last UpdatedBias Distribution100% Left
Bias Distribution
- 100% of the sources lean Left
100% Left
L 100%
Factuality
To view factuality data please Upgrade to Premium
